You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK)主要股東兼首席執行長謝炳擬配售2億股
格隆匯 04-21 06:46

格隆匯4月21日丨中國生物製藥(01177.HK)公佈,公司董事會獲謝炳先生(為公司首席執行長、執行董事及主要股東)告知,於2020年4月21日,謝先生(作為賣方)與公司的獨立第三方(作為管理人)訂立一份配售協議,促使承配人按配售價每股配售股份11.35港元購買2億股公司股份。

目前預期配售事項將於2020年4月23日完成。於完成後,謝先生實益擁有的股份數目將減少至11.84億股股份,相當於公司已發行股本約9.40%。

董事會預期,配售事項將不會對公司及其附屬公司的業務或營運產生任何影響。董事會的組成維持不變,並且公司現時管理團隊將繼續負責公司的日常營運及管理,該管理團隊將繼續由謝炳先生及其家族成員(包括鄭翔玲女士、謝其潤女士及謝承潤先生)領導。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account